California-based Ionis Pharmaceuticals has announced it has licensed to AstraZeneca its investigational therapy Ionis-AZ6-2.5, developed to treat patients with Non-Alcoholic Steatohepatitis (NASH). This is the third therapy obtained from the partnership between the firms. Under the terms of the agreement, AstraZeneca will be responsible for the therapy’s development and subsequent marketing; Ionis will receive $300m in exchange for the asset. Ionis has already received royalties for a total $65m value as part of the partnership with AstraZeneca started in 2015, aimed at developing new therapies in areas such as cardiovascular, metabolic and kidney diseases. Ionis’ shares have risen over 3% soon after the announcement.